Melittin derived peptides for nanoparticle based siRNA transfection

Biomaterials

Volumn 34, Issue 12, 2013, Pages 3110-3119

  Hou, Kirk K ^a   Pan, Hua ^a   Lanza, Gregory M ^a   Wickline, Samuel A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug delivery; Endothelial cell; Gene therapy; Macrophage; Nanoparticle

Indexed keywords

ALTERNATIVE METHODS; ANGIOGENESIS; B16 CELLS; CATIONIC LIPIDS; CELL-PENETRATING PEPTIDE; FOAM CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; IN-VITRO; IN-VIVO; MELITTIN; SERUM PROTEINS; TRANSFECTION AGENTS; TRANSFECTION EFFICIENCY;

CELL PROLIFERATION; CELLULAR MANUFACTURING; CYTOTOXICITY; DRUG DELIVERY; EFFICIENCY; ENDOTHELIAL CELLS; GENE THERAPY; MACROPHAGES; NANOPARTICLES; PEPTIDES;

MOLECULAR BIOLOGY;

GREEN FLUORESCENT PROTEIN; MELITTIN; NANOPARTICLE; PROTEIN; SMALL INTERFERING RNA;

ANGIOGENESIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; FOAM CELL; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; CELL LINE; CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; MELITTEN; MICE; NANOPARTICLES; PEPTIDES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84873433098     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.01.037     Document Type: Article

References (56)

1. Shen H., Sun T., Ferrari M. Nanovector delivery of siRNA for cancer therapy. Cancer Gene Ther 2012, 19:367-373.
2. Miele E., Spinelli G.P., Miele E., Fibrizio E.D., Ferretti E., Tomao S., et al. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int J Nanomedicine 2012, 7:3637-3657.
3. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
4. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
5. Wang J., Lu Z., Wientjes J.G., Au J.L.S. Delivery of siRNA therapeutics: barriers and carriers. AAPS J 2010, 12:492-503.
6. Aigner A. Cellular delivery in vivo of siRNA-based therapeutics. Curr Pharm Des 2008, 14:3603-3619.
7. Dominska M., Dykxhoorn D.M. Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci 2010, 123:1183-1189.
8. Varkouhi A.K., Scholte M., Storm G., Haisma H.J. Endosomal escape pathways for delivery of biologicals. J Control Release 2011, 151:220-228.
9. Kwon Y.J. Before and after endosomal escape: roles of stimuli-converting siRNA/polymer interactions in determining gene silencing efficiency. Acc Chem Res 2012, 45:1077-1088.
10. Gilmore I.R., Fox S.P., Hollins A.J., Akhta S. Delivery strategies for siRNA-mediated gene silencing. Curr Drug Deliv 2006, 3:147-155.
11. Nimesh S., Gupta N., Chandra R. Strategies and advances in nanomedicine for targeted siRNA delivery. Nanomedicine 2011, 6:729-746.
12. Guzman-Villanueva D., El-Sherbiny I.M., Herrera-Ruiz D., Vlassov A.V., Smyth H.D.C. Formulation approaches to short interfering RNA and mircoRNA: challenges and implications. J Pharm Sci 2012, 101:4046-4066.
13. Lv H., Zhang S., Wang B., Cui S., Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 2006, 114:100-109.
14. Filion M.C., Phillips N.C. Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim Biophys Acta 1997, 1329:345-356.
15. Soenen S.J.H., Brisson A.R., De Cuyper M. Addressing the problem of cationic lipid-mediated toxicity: the magnetoliposome model. Biomaterials 2009, 30:3691-3701.
16. Park K., Lee M.-Y., Kim K.S., Hahn S.K. Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine-hyaluronic acid conjugate. Biomaterials 2012, 31:5258-5265.
17. Maruyama K., Iwasaki F., Takizawa T., Yanagie H., Nidome T., Etsuko Y., et al. Novel receptor-mediated gene delivery system comprising plasmid/protamine/sugar-containing polyanion ternary complex. Biomaterials 2004, 25:3267-3273.
18. Schroeder A., Levins C.G., Cortez C., Langer R., Anderson D.G. Lipid-based nanotherapeutics for siRNA delivery. J Intern Med 2009, 267:9-21.
19. Chen D., Love K.T., Chen Y., Eltoukhy A.A., Kastrup C., Sahay G., et al. Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation. J Am Chem Soc 2012, 134:6948-6951.
20. Plank C., Mechtler K., Szoka F.C., Wagner E. Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Hum Gene Ther 1996, 7:1437-1446.
21. Abes R., Arzumanov A.A., Moulton H.M., Abes S., Ivanova G.D., P.I I., et al. Cell-penetrating-peptide-based delivery of oligonucleotides: an overview. Biochem Soc Trans 2007, 35:775-779.
22. Morris M.C., Deshayes S., Heitz F., Divita G. Cell-penetration peptides: from molecular mechanisms to therapeutics. Biol Cell 2008, 100:201-217.
23. Meade B.R., Dowdy S.F. Enhancing the cellular uptake of siRNA duplexes following noncovalent packaging with protein transduction domain peptides. Adv Drug Deliv Rev 2008, 60:530-536.
24. Endoh T., Ohtsuki T. Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape. Adv Drug Deliv Rev 2009, 61:704-709.
25. Laufer S.D., Detzer A., Sczakiel G., Restle T. Selected strategies for the delivery of siRNA in vitro and in vivo. RNA technologies and their applications 2010, 29-58. Springer-Verlag, Berlin. V.A. Erdmann, J. Barciszewski (Eds.).
26. Veldhoen S., Laufer S.D., Trampe A., Restle T. Cellular delivery of small interfering RNA by a non-covalently attached cell-penetrating peptide: quantitative analysis of uptake and biological effect. Nucleic Acids Res 2006, 34:6561-6573.
27. Crombez L., Morris M.C., Deshayes S., Heitz F., Divita G. Peptide-based nanoparticle for ex vivo and in vivo drug delivery. Curr Pharm Des 2008, 14:3656-3665.
28. Deshayes S., Gerbal-Chaloin S., Morris M.C., Aldrian-Herrada G., Charnet P., Divita G., et al. On the mechanism of non-endosomal peptide-mediated cellular delivery of nucleic acids. Biochim Biophys Acta 2004, 1667:141-147.
29. Kim S.W., Kim N.Y., Choi Y.B., Park S.H., Yang J.M., Shin S. RNA interference in vitro and in vivo using an arginine peptide/siRNA complex system. J Control Release 2010, 143:335-343.
30. Kim J., Lee S.H., Choe J., Park T.G. Intracellular small interfering RNA delivery using genetically engineered double-stranded RNA binding protein domain. J Gene Med 2009, 11:804-812.
31. Ezzat K., Andaloussi S.E.L., Zaghloul E.M., Lehto T., Lindberg S., Moreno P.M.D., et al. Pepfect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. Nucleic Acids Res 2011, 39:5284-5298.
32. Arthanari Y., Pluen A., Rajendran R., Aojla H., Demonarcos C. Delivery of therapeutic shRNA and siRNA by tat fusion peptide targeting BCR-ABL fusion gene in chronic myeloid leukemia cells. J Control Release 2010, 145:272-280.
33. Mae M., Andaloussi S.E., Lehto T., Langel U. Chemcially modified cell-penetrating peptides for the delivery of nucleic acids. Expert Opin Drug Deliv 2009, 6:1195-1205.
34. Pan H., Ivashyna O., Sinha B., Lanza G.M., Ratner L., Schlesinger P.H., et al. Post-formulation peptide drug loading of nanostructures for metered control of NF-kB signaling. Biomaterials 2011, 32:231-238.
35. Pan H., Marsh J.N., Christenson E.T., Soman N.R., Ivashyna O., Lanza G.M., et al. Chapter two - postformulation peptide drug loading of nanostructures. Methods Enzymol 2012, 508:17-39.
36. Corish P., Tyler-Smith C. Attenuation of green fluorescent protein half-life in mammalian cells. Protein Eng Des Sel 1999, 12:1035-1040.
37. Heitz F., Morris M.C., Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol 2009, 157:195-206.
38. Mankan A.K., Greten F.R. Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors. Expert Opin Invest Drugs 2011, 20:1263-1275.
39. Zhao M., Jiang B., Gao F.-H. Small molecule inhibitors of STAT3 for cancer therapy. Curr Med Chem 2011, 18:4012-4018.
40. Yang C.H., Fan M., Slominski A.T., Yue J., Pfeffer L.M. The role of consitutively activated STAT3 in B16 melanoma cells. Int J Infereron Cytokine Mediator Res 2010, 2:1-7.
41. Bartoli M., Platt D., Lemtalsi T., Gu X., Brooks S.E., Marrero M.B., et al. VEGF differentially activates STAT3 in microvascular endothelial cells. FASEB J 2003, 17:1562-1564.
42. Yahata Y., Shirakata Y., Tokumaru S., Yamasaki K., Sayama K., Hanakawa Y., et al. Nuclear translocation of phosphorylated STAT3 is essential for vascular endothelial growth factor-induced human dermal microvascular endothelial migration and tube formation. J Biol Chem 2003, 278:40026-40031.
43. Deo D.D., Axelrad W., Robert E.G., Marcheselli V., Bazan N.G., Hunt J.D. Phosphorylation of STAT-3 in response to basic fibroblast growth factor occurs through a mechanism involving platelet-activation factor, JAK-2, and src in human umbilical vein endothelial cells. J Biol Chem 2002, 277:21237-21245.
44. Bid H.K., Oswald D., Li C., London C.A., Lin J., Houghton P.J. Anti-angiogenic activity of a small molecule STAT3 inhibitor LLL12. PLoS ONE 2012, 7:e35513.
45. Zhang H., Zhang L., Myerson J., Bibee K., Scott M., Allen J., et al. Quantifying the evolution of vascular barrier disruption in advanced atherosclerosis with semipermeant nanoparticle contrast agents. PLoS ONE 2011, 6:e26385.
46. Ricci R., Sumara G., Sumara I., Rozenberg I., Kurrer M., Akhmedov A., et al. Requirement of JNK2 for scavenger receptor A-mediated foam cell formation. Science 2004, 306:1558-1561.
47. Rahaman S.O., Lennon D.J., Febbraio M., Podrez E.A., Hazen S.L., Silverstein R.L. A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell Metab 2006, 4:211-221.
48. Kaneda M.M., Sasaki Y., Lanza G.M., Milbrandt J., Wickline S.A. Mechanisms of nucleotide trafficking during siRNA delivery to endothelial cells using perfluorocarbon nanoemulsions. Biomaterials 2010, 31:3079-3086.
49. Lundberg P., Andaloussi S.E., Sutlu T., Johansson H., Langel U. Delivery of short interfering RNA using endosomolytic cell-penetrating peptides. FASEB J 2007, 21:2664-2671.
50. Li Y., Wang J., Gao Y., Zhu J., Wientjes J.G., Au J.L.S. Relationships between liposome properties, cell membrane binding, intracellular processing, and intracellular bioavailability. AAPS J 2011, 13:585-597.
51. Chou S.-T., Leng Q., Scaria P., Woodle M., Mixson A.J. Selective modification of HK peptides enhances siRNA silencing of tumor targets in vivo. Cancer Gene Ther 2011, 18:707-716.
52. Pichon C., Roufai M.B., Monsigny M., Midoux P. Histidylated oligolysines increase the transmembrane passage and the biological activity of antisense oligonucleotides. Nucleic Acids Res 2000, 28:504-512.
53. Schenkman S., Araujo P.S., Dijkman R., Quina F.H., Chaimovich H. Effects of temperature and lipid composition on the serum albumin-induced aggregation and fusion of small unilamellar vesicles. Biochim Biophys Acta 1981, 649:633-641.
54. Simoes S., Slepushkin V., Pires P., Gaspar R., Pedroso M.C., Duzgunes N. Human serum albumin enhances DNA transfection by lipoplexes and confers resistance to inhibition by serum. Biochim Biophys Acta 2000, 1463:459-469.
55. Kaneda M.M., Caruthers S., Lanza G.M., Wickline S.A. Perfluorocarbon nanoemulsions for quantitative molecular imaging and targeted therapeutics. Ann Biomed Eng 2009, 37:1922-1933.
56. Crombez L., Divita G. A non-covalent peptide-based strategy for siRNA delivery. Cell-penetrating peptides: methods and protocols 2011, 349-360. Humana Press, New York, NY. U. Langel (Ed.).